Brief: Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis
03/06/2025 12:02
June 3 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O: AMYLYX PHARMACEUTICALS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR AMX0114 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AMYLYX PHARMACEUTICALS INC - PHASE 1 LUMINA TRIAL UNDERWAY, DATA EXPECTED IN 2025 Source text: ID:nBw6vfLjna Further company coverage: AMLX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock